biote (BTMD) to Release Earnings on Wednesday

biote (NASDAQ:BTMD - Get Free Report) is expected to issue its Q1 2025 quarterly earnings data after the market closes on Wednesday, May 7th. Analysts expect biote to post earnings of $0.06 per share and revenue of $47.25 million for the quarter.

biote Trading Down 2.7 %

Shares of biote stock traded down $0.10 during trading hours on Monday, reaching $3.39. 28,480 shares of the company's stock were exchanged, compared to its average volume of 187,940. biote has a fifty-two week low of $3.04 and a fifty-two week high of $8.44. The stock has a market cap of $185.19 million, a P/E ratio of 12.95 and a beta of 1.17. The company has a 50 day moving average of $3.68 and a two-hundred day moving average of $4.99.

Analysts Set New Price Targets

Separately, Craig Hallum dropped their price objective on biote from $12.00 to $8.00 and set a "buy" rating on the stock in a research note on Thursday, March 13th.

Insider Activity

In other biote news, Director Stephen Mark Cone purchased 38,104 shares of the business's stock in a transaction on Monday, March 17th. The stock was acquired at an average price of $3.88 per share, with a total value of $147,843.52. Following the acquisition, the director now directly owns 160,829 shares of the company's stock, valued at $624,016.52. This trade represents a 31.05 % increase in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Also, major shareholder Guines Llc acquired 8,801 shares of the firm's stock in a transaction on Monday, April 21st. The stock was bought at an average price of $3.27 per share, for a total transaction of $28,779.27. Following the completion of the acquisition, the insider now owns 4,173,101 shares of the company's stock, valued at approximately $13,646,040.27. The trade was a 0.21 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders bought a total of 976,043 shares of company stock valued at $3,176,710 in the last quarter. Company insiders own 24.00% of the company's stock.

About biote

biote Corp. operates in practice-building business within the hormone optimization space. It trains physicians and nurse practitioners in hormone optimization using bioidentical hormone replacement pellet therapy in men and women experiencing hormonal imbalance. The company offers Biote Method, a comprehensive end-to-end practice building platform that provides Biote-certified practitioners with the components developed for practitioners in the hormone optimization space comprising Biote Method education, training, and certification services; practice management software that allows Biote-certified practitioners to order, track, and manage hormone optimization product inventory and other administrative requirements; inventory management software to monitor pellet inventory; and information regarding available hormone replacement therapy products, as well as digital and point-of-care marketing support.